NCT06363825招募中2 期
Single-arm, Prospective Clinical Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma With High Tumor Load
Fujian Medical University1 个研究点 分布在 1 个国家目标入组 57 人开始时间: 2024年4月12日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 57
- 试验地点
- 1
- 主要终点
- Objective response rate (ORR)
研究概览
简要总结
To evaluate the efficacy and safety of TAE+HAIC combined with camrelizumab and apatinib in the treatment of advanced liver cancer with high tumor load
详细描述
At present, there are no prospective clinical studies using the combination regimen (TAE+HAIC+ Apatinib + camrelizumab) in the treatment of advanced liver cancer. Therefore, in this study, investigators designed a single-arm, prospective, multicenter, phase Ⅱ clinical study of arterial infusion of TAE+HAIC+ Apatinib + camrelizumab in the treatment of advanced liver cancer with high tumor load, to explore the safety and efficacy of this regimen. If study gets positive results, it will provide a reference for the subsequent phase Ⅲ clinical trial design, which is expected to provide a new effective approach for the treatment of advanced liver cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The subjects voluntarily joined the study, had good compliance, cooperated with follow-up, and obtained written informed consent;
- •Age: 18 years old ≤80 years old, both male and female;
- •In accordance with the "Norms for the Diagnosis and Treatment of Primary Liver Cancer (2022 edition)" formulated by the National Health Commission and the 2018 EASL liver Cancer guidelines formulated by the European Association for the Study of Hepatology, a definite diagnosis of hepatocellular carcinoma has been made and pathological results have been obtained;
- •There is at least one measurable lesion (spiral CT scan diameter ≥10mm or malignant lymph node short diameter ≥15mm according to RECIST1.1 standard, see Annex 5 for RECIST version 1.1);
- •Have not received systematic treatment before;
- •6.CNLC was divided into stages Ⅱa-Ⅲb;
- •Meet the status of high tumor load, and meet one of the following conditions: 1) High tumor load is defined according to the 7-11 criteria: combined with the number of tumors and the maximum tumor size, high tumor load is defined as and > 11; 2) Combined with primary branch of portal vein and main cancer thrombus;
- •The Child-Pugh classification of liver function is grade A or B (5-8 points);
- •9.ECOG PS score 0-1;
- •Expected survival ≥12 weeks;
- •If the patient has active hepatitis B virus (HBV) infection: if HBV-DNA≤2000, treatment can be started directly; If HBV-DNA > 2000, start antiviral therapy for one week and then start treatment.
- •The major organs function properly and meet the following criteria:
- •The standard of blood routine examination must meet: (no blood transfusion within 14 days)
- •Hemoglobin (HB) ≥100g/L,
- •White blood cell count (WBC)≥3×10^9/L
- •Absolute neutrophil count (ANC)≥1.5×10^9/L,
- •Platelet (PLT)≥50×10^9/L;
- •Biochemical examination shall meet the following standards:
- •Bilirubin (BIL)<1.5 times the upper limit of normal (ULN);
- •Alanine aminotransferase (ALT) and aspartate aminotransferase AST<5ULN;
- •Serum creatinine (Cr) ≤1.5ULN
- •Women of childbearing age must have a negative pregnancy test (serum) or urine HCG test within 7 days prior to admission and be willing to use an appropriate method of contraception during the trial period and 8 weeks after the last dose of the test drug; For men, they should be surgically sterilized or consent to an appropriate method of contraception during the trial and for 8 weeks after the last dose of the trial drug.
排除标准
- •Pregnant or lactating women;
- •Patients with autoimmune diseases, organ/hematopoietic stem cell transplantation, or other malignancies (except cured skin basal cell carcinoma and cervical carcinoma in situ);
- •Patients with consciousness disorder or inability to cooperate with treatment, combined with mental illness;
- •Patients who have participated in other clinical trials in the past three months;
- •Received local treatment (such as surgical resection, radiation therapy, ablative therapy, interventional therapy, etc.) within the past 1 month;
- •Thrombotic or embolic events, such as cerebrovascular accidents (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism, except portal vein thrombosis, occurred within 6 months prior to the first dose of the study drug;
- •Immunosuppressants or systemic hormone therapy (dose >10mg/ day prednisone or other therapeutic hormones) were used within 14 days before enrollment to achieve immunosuppression;
- •Esophageal (fundus) varices rupture and bleeding within 1 month before treatment;
- •Uncorrectable coagulation dysfunction and severe blood abnormalities, with a tendency to severe bleeding; Platelet count < 50×109/L and severe coagulation dysfunction can not withstand surgery (anticoagulant therapy and/or anticoagulant drug use should be stopped more than 1 week before radiotherapy);
- •Refractory ascites, bad fluid;
- •Active infection, especially inflammation of the biliary system;
- •Severe liver, kidney, heart, lung, brain and other major organ failure;
- •Previous use of targeted drugs, any component of PD-1 MAB or other similar tests A quick person;
- •Patients with hypertension who cannot be reduced to the normal range by antihypertensive medication (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg);
- •Previous serious cardiovascular disease, including but not limited to the following diseases: Grade II or above myocardial ischemia or myocardial infarction, poorly controlled arrhythmias (including QTc interval ≥450 ms in men and ≥470 ms in women); According to NYHA criteria, patients with grade Ⅲ to Ⅳ cardiac insufficiency or left ventricular ejection fraction (LVEF) < 50% indicated by cardiac color ultrasound;
- •Patients with positive urinary protein (urinary protein test 2+ or more, or 24-hour urinary protein quantity > 1.0g);
- •Inability to swallow tablets, malabsorption syndrome or any condition affecting gastrointestinal absorption;
- •Patients with other concomitant diseases that, in the judgment of the investigator, endanger the patient's safety or interfere with the patient's completion of the study.
- •Patients who do not wish to undergo histological examination to confirm the diagnosis.
研究组 & 干预措施
Single arm
Experimental
TAE+HAIC combined with camrelizumab and apatinib
干预措施: camrelizumab (Drug)
结局指标
主要结局
Objective response rate (ORR)
时间窗: 1 years
Refers to the proportion of all subjects with a best overall result (BOR) of complete remission (CR) or partial remission (PR) as rated according to RECIST 1.1 criteria. If efficacy of CR or PR is achieved, subjects must be confirmed not less than 4 weeks ± 7 days after the initial evaluation.
次要结局
- Overall survival (OS)(3 years)
- Progression-free survival (PFS)(1 years)
- AE(1 years)
- Disease control rate (DCR)(1 years)
- Tumor progression time (TTP)(1 years)
研究者
Yiping Chen
Associate professor
Fujian Medical University
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar CarcinomaHepatocellular CarcinomaNCT04559607Zhongda Hospital188
Unknown
2 期
A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs).Immune Checkpoint InhibitorsHepatocellular CarcinomaNCT04826406Hunan Cancer Hospital40
Unknown
不适用
Camrelizumab Combined With Apatinib in the Treatment of Epithelial Ovarian CancerImmune Checkpoint InhibitionNCT04507750Qianfoshan Hospital40
Unknown
2 期
Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal CarcinomaNasopharyngeal CarcinomaNCT04548271Sun Yat-sen University25
尚未招募
2 期
Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract CancerCarcinomaGallbladder CancerSurufatinibAngiogenesis InhibitorsTislelizumabAntineoplastic Agents, ImmunologicalImmunotherapyIntrahepatic CholangiocarcinomaNCT06134193Wuhan Union Hospital, China41